ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Biofrontera (BFRI)
Biofrontera stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · NASDAQ
$0.84▲ +2.10%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Biofrontera in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Biofrontera
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Biofrontera a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $0.72 and $0.94; in 9 out of 10, between $0.57 and $1.19. Estimated annual volatility is 69%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $15.1M
- 52-week high
- $1.66
- 52-week low
- $0.56
- Revenue (12 months)
- $46.2M
- Revenue growth (YoY)
- +11.8%
- Gross margin
- 73.7%
- Operating margin
- -27.2%
- Net margin
- -25.3%
- Free cash flow (12 months)
- $-7.6M
- Beta
- 0.84
What this means
ATLAS does not publish a fair value for BFRI right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks BFRI has traded between $0.56 and $1.66. Today it is 49.4% below that high and 50% above its low.
On the business: revenue grew 11.8% year over year; net margin is 25.3%.
Its beta is 0.84: it tends to move less than the market.
About the company
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology products with an emphasis on photodynamic therapy.
Want to see everything about Biofrontera?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Biofrontera do?
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology products with an emphasis on photodynamic therapy.
What is the chance BFRI goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, BFRI ends the month between $0.72 and $0.94.
How big is Biofrontera and what is its P/E ratio?
Biofrontera's market capitalization is $15.1M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is BFRI?
ATLAS estimates annual volatility at 69%. In a typical month, half of the outcomes end between $0.72 and $0.94.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer